ATOMO DIAGNOSTICS

Q4 FY26 QUARTERLY REPORT

23 JULY 2026

Q4 FY26 HIGHLIGHTS

FINANCIAL HIGHLIGHTS

- **Revenue for the period of $2.3 million, bringing total revenue for the FY26 of $5.3 million** *(unaudited)*
    - *This represents an **increase of 40%** in revenue compared to FY25*
- **Sales orders worth more than $1.5 million also received during the quarter**
- **Cash receipts for the period totaling $3.8 million (further cash receipts of ~$1 million to date in July)**
    - *Cash on hand of $3.7 million at 30 June 2026 and the company remains debt free*

BUSINESS HIGHLIGHTS

- **Onboarded Pharmacies in Australia selling the Atomo HIV Self-Test increases 33% during the quarter** (from 147 to 196 – more growth anticipated during FY27)
- **Successful completion of Pascal orders received Jan 2026 for two new OEM customers** – supports long-term supply agreements; anticipated during Q1 FY27
- **Progressing business planning and market engagement for the Atomo Liver function test** - focus initially on liver function monitoring for patients prescribed at-risk drugs
- **Set up and operation of blister Machine (Gen 2) at an Atomo facility, Sydney**
    - *Qualification to support product dossiers and QMS (Quality System) upgrades commencing*

APPENDIX 4C OVERVIEW

Name of Entity

Atomo Diagnostics Limited

ABN	Quarter Ended ("current quarter")
37 142 925 684	30 June 2026

Consolidated statement of cash flows		Current Quarter A$'000	Year to date (12 months) A$'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	904	4,456
1.2	Payments for		
	(a) research and development	(91)	(560)
	(b) product manufacturing and operating costs	(1,555)	(4,789)
	(c) advertising and marketing	(21)	(147)
	(d) leased assets	-	-
	(e) staff costs	(703)	(2,694)
	(f) administration and corporate costs	(336)	(1,245)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	24	75
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	165	1,535
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**(1,614)**	**(3,369)**

Consolidated statement of cash flows		Current Quarter A$'000	Year to date (12 months) A$'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,605	3,220
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,614)	(3,369)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9)	(50)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,653	3,816
4.5	Effect of movement in exchange rates on cash held	74	92
4.6	**Cash and cash equivalents at end of period**	3,709	3,709

8.	**Estimated cash available for future operating activities**	**A$'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(1,614)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	3,709
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	3,709
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	2.30

In accordance with ASX Listing Rule 4.7C.3, Atomo advises that an amount of $148k was paid during the quarter covering Atomo's Managing Director salary and Non-Executive Directors fees.

Q4 FINANCIAL HIGHLIGHTS

CASH FLOW ACTIVITIES



- **Cash receipts for the quarter totaled $3.8m** made up of $1m customer receipts, $165k from the Syphilis CRC-P grant and ~$2.7m from placement funds net transaction costs.
- Cash outflows totaled $2.8m for the quarter - continued focus on product supply, efforts progressing new programs and operational expansion/improvements
- Cash on hand as at Q4 FY26 finished at $3.7m

REVENUES



- **Revenue of $2.3m, bringing YTD revenue to ~$5.3m** (up 40% on FY25)
    - HIV sales of ~$1.6m
    - OEM ~$670k: increased orders for Pascal - FebriDx and two new customers
- Further orders worth >$1.5 million received during the period

OPERATING COSTS

- Operating expenses, totaling $1.4m for the quarter, continues to be managed and deployed towards revenue growth opportunities
- This does note take into account other income from the CRC-P grant and government R&D rebates, further improving bottom line by >15%



FINANCIAL SUMMARY

- ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Testing and Pascal OEM
- ✓ Expansion of customer base across new partners for Pascal and an expanded Atomo test product pipeline



- ✓ Capital focus on new test portfolio development / commercialisation – Syphilis and Liver
- ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support lower-cost development and go to market
- ✓ EBITDA – continued trend towards breakeven as existing revenue channels grow and product offerings expand

- ✓ **Debt free balance sheet**
- ✓ Atomo validating a second-generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale and margins



EXPANDING TEST PORTFOLIO

Building a portfolio of innovative point-of-care rapid diagnostic tests for global markets

PRODUCT	INDICATION	DEVELOPMENT / VALIDATION & REGULATORY APPROVAL / LAUNCH
HIV LAUNCHED	HIV Detection (Self-Testing)	● LAUNCHED – ANZ, UK & LMIC
	HIV Detection (Professional Use)	● APPROVED – OPPORTUNITY FOR GEN IV UPGRADE
Pregnancy Market ready	Pregnancy Detection (Self & Professional)	● LAUNCHING – Europe. ATOMO MARKETS TO FOLLOW
Syphilis PIPELINE	Distinguish active vs prior treated infection	▶ DEVELOPMENT COMPLETE – CLINICAL TRIALS COMMENCING 2026
Liver / ALT PIPELINE	Liver disease screening & monitoring	▶ TEST DEVELOPMENT COMPLETE – CLINICAL GO TO MARKET DEVELOPMENT COMMENCED

TESTS UNDER CONSIDERATION	**PSA**	**Stroke**	**Coeliac**	**HIV Gen 4**	**Others TBD**
	Prostate cancer screening	*Acute neurological triage*	*Gluten sensitivity detection*	*4th generation HIV detection*	*Subject to commercial assessment*

HIV BUSINESS ACTIVITY

Australian Pharmacy Growing Momentum

- **190 pharmacies active** in Australia
- **Target to grow 6x** over the next 3 years
- **49 new pharmacies** added this quarter

New Zealand – Expansion and foundation established

- **70 pharmacies activated** since launch in FY25
- **Target to grow 8x** over the next 3 years
- CDC (Pharmacy Wholesaler) commenced ordering this quarter

Australia Government Program

- Rollover order from key government programs
- **NAPWHA demand has grown 275% over the last 24 months**

International HIV Business

Significant growth underway across European and LMIC markets



ACTIVE SYPHILIS – HIGH-LEVERAGE EXPANSION

Addressing significant unmet clinical and market needs

- no existing rapid test can reliably distinguish active & prior infection
- no current test format is optimised for easy, reliable self-testing

Established demand via existing HIV channels

Channel Leverage — Similar users, public buyers and distribution channels

Efficiency — Lower cost of entry, faster time to launch and scale revenue

Development & Commercial Readiness:

- **Product Development & Initial Verification Complete**

Strong product verification and preliminary clinical data supporting commercial interest *(Sensitivity greater than 85% for active syphilis detection is market leading)*

- **Technology Transfer commenced for Manufacturing (Q4 FY26 and Q1 FY27)**

Enabling product for formal clinical trials and reg. submissions and validating manufacturing processes

- **Clinical Trials commencing mid FY27**

Clinical validation planning underway and progressing toward commercialisation

- **Initial engagement with Regulator successfully completed**

Positive engagement with clinicians and key stakeholders to support market access

Q4 ACTIVITY – ALT / LIVER TEST

01

Drug-Induced Liver Injury (DILI)

Monitoring for common drug types requiring ALT surveillance — TB drugs, Methotrexate, Leflunomide, Azathioprine, Valproate, Amiodarone, long-term Diclofenac.

Evaluation underway in US trial by multinational pharmaceutical company

Drug-Induced Liver Injury (DILI)

2025 SOM - A$72M
2032 SOM – A$100M

03

Fatty Liver Disease Screening

High correlation between elevated ALT and fatty liver disease — affecting 1.5B+ people globally. Significant opportunity for home screening and monitoring of at-risk and diagnosed patients.

Fatty Liver Disease

2032 SOM – A$80M

- **Commercial pathway:** Confirming priority use case for clinical-trials and doctor prescribed at-home liver monitoring
- **Partner development:** Engage with pharmaceutical, CRO or commercial partners during FY27
- **KOL engagement:** Engagement commenced with clinical leaders in key channels – DILI / pharmaceutical conferences and Fatty Liver disease KOLs

- **Partner development:** Engage with Australian clinical KOL's and public health to assess use of a screening test across high-risk cohorts for Fatty Liver disease
- **Assess funding opportunities for this application:** Fatty Liver disease has a very large public health cost globally generating interest from governments

Q4 OPERATIONAL UPDATE

- **Blister Machine (Gen 2) -** successfully relocated to an Atomo-operated facility in Sydney. Equipment qualification completed. This facility will be integrated into Atomo's Quality Management System (QMS) in the coming months

- **Improved capacities and margins** - Blister machine 2 coming online under Atomo operations, combined with qualification of high cavitation tooling (underway) will increase validated Pascal production volumes and improve margins; especially OEM supply of Pascal to partners

- **New Pascal Customer Operations** - Pascal cassettes for new OEM customers secured Q3 FY26 – Chromacare, Canada and a UK company – delivery expected to facilitate long-term supply deals with these two companies – agreements anticipated during Q1 FY27

Atomo Q4 FY26 Quarterly Investor Webinar Presentation

Atomo Diagnostics Limited will hold its Q4 FY26 Quarterly Investor webinar on Friday 24th July 2026 at 11am (AEST).

To access the webinar please pre-register by clicking this link

For further information, please contact:

John Kelly Managing Director & CEO
john.kelly@atomodiagnostics.com
p. +61 401 922 279

Investor Queries investor
queries@atomodiagnostics.com

Rule 4.7B

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of Entity

Atomo Diagnostics Limited

ABN	Quarter Ended ("current quarter")
37 142 925 684	30 June 2026

Consolidated statement of cash flows		Current Quarter A$'000	Year to date (12 months) A$'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	904	4,456
1.2	Payments for		
	(a) research and development	(91)	(560)
	(b) product manufacturing and operating costs	(1,555)	(4,789)
	(c) advertising and marketing	(21)	(147)
	(d) leased assets	-	-
	(e) staff costs	(703)	(2,694)
	(f) administration and corporate costs	(336)	(1,245)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	24	75
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	165	1,535
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**(1,614)**	**(3,369)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(9)	(50)
	(d) investments	-	-
	(e) intellectual property	(0)	(0)
	(f) other non-current assets	-	

Consolidated statement of cash flows		Current Quarter A$'000	Year to date (12 months) A$'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(9)**	**(50)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,005	4,408
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(283)	(348)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(68)	(244)
3.7	Transaction costs related to loans and borrowings	-	
3.8	Dividends paid	-	
3.9	Other (provide details if material)	-	
3.10	**Net cash from / (used in) financing activities**	**2,653**	**3,816**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,605	3,220
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,614)	(3,369)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9)	(50)

Consolidated statement of cash flows		Current Quarter A$'000	Year to date (12 months) A$'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,653	3,816
4.5	Effect of movement in exchange rates on cash held	74	92
4.6	**Cash and cash equivalents at end of period**	3,709	3,709

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current Quarter A$'000**	**Previous Quarter A$'000**
5.1	Bank balances	3,709	3,512
5.2	Term deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**3,709**	**3,512**

6.	**Payments to related parties of the entity and their associates**	**Current Quarter A$'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	148
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility" includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity*	**Total facility amount at quarter end A$'000**	**Amount drawn at quarter end A$'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangement	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**A$'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(1,614)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	3,709
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	3,709
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**2.30**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Not applicable.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Not applicable.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Not applicable.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 23 July 2026

Authorised by: ....The Board
(Name of body or officer authorising release see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the *[name of board committee – eg Audit and Risk Committee]* ". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.